Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4869960
Max Phase: Preclinical
Molecular Formula: C43H45ClFN9O7
Molecular Weight: 854.34
Molecule Type: Unknown
Associated Items:
ID: ALA4869960
Max Phase: Preclinical
Molecular Formula: C43H45ClFN9O7
Molecular Weight: 854.34
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCN(C(=O)CCCCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1
Standard InChI: InChI=1S/C43H45ClFN9O7/c1-2-36(55)50-33-23-28-32(47-25-48-40(28)49-26-11-12-30(45)29(44)22-26)24-35(33)61-21-7-16-52-17-19-53(20-18-52)38(57)10-4-3-5-15-46-31-9-6-8-27-39(31)43(60)54(42(27)59)34-13-14-37(56)51-41(34)58/h2,6,8-9,11-12,22-25,34,46H,1,3-5,7,10,13-21H2,(H,50,55)(H,47,48,49)(H,51,56,58)
Standard InChI Key: UFVWZVUFBJDPFK-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 854.34 | Molecular Weight (Monoisotopic): 853.3115 | AlogP: 5.28 | #Rotatable Bonds: 17 |
Polar Surface Area: 195.27 | Molecular Species: NEUTRAL | HBA: 12 | HBD: 4 |
#RO5 Violations: 3 | HBA (Lipinski): 16 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.55 | CX Basic pKa: 6.88 | CX LogP: 4.45 | CX LogD: 4.33 |
Aromatic Rings: 4 | Heavy Atoms: 61 | QED Weighted: 0.06 | Np Likeness Score: -1.20 |
1. Qu X, Liu H, Song X, Sun N, Zhong H, Qiu X, Yang X, Jiang B.. (2021) Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems., 218 [PMID:33773286] [10.1016/j.ejmech.2021.113328] |
Source(1):